DLA Piper advises Histogen in its US$14 million upsized public offering
DLA Piper advises Histogen in its US$14 million upsized public offering News provided by Share this article Share this article NEW YORK, Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natural process to repair and maintain healthy biological function, in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14...